Literature DB >> 18988797

Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.

Jesús M Banales1, Tatyana V Masyuk, Pamela S Bogert, Bing Q Huang, Sergio A Gradilone, Seung-Ok Lee, Angela J Stroope, Anatoliy I Masyuk, Juan F Medina, Nicholas F LaRusso.   

Abstract

Polycystic kidney (PCK) rats are a spontaneous model of autosomal recessive polycystic kidney disease that exhibit cholangiocyte-derived liver cysts. We have previously reported that in normal cholangiocytes a subset of vesicles contain three proteins (ie, the water channel AQP1, the chloride channel CFTR, and the anion exchanger AE2) that account for ion-driven water transport. Thus, we hypothesized that altered expression and location of these functionally related proteins contribute to hepatic cystogenesis. We show here that under basal conditions and in response to secretin and hypotonicity, cysts from PCK rats expanded to a greater degree than cysts formed by normal bile ducts. Quantitative reverse transcriptase-polymerase chain reaction, immunoblot analysis, and confocal and immunoelectron microscopy all indicated increased expression of these three proteins in PCK cholangiocytes versus normal cholangiocytes. AQP1, CFTR, and AE2 were localized preferentially to the apical membrane in normal rats while overexpressed at the basolateral membrane in PCK rats. Exposure of the cholangiocyte basolateral membrane to CFTR inhibitors [5-nitro-2-(3-phenylpropylamino)-benzoic acid and CFTRinh172], or Cl(-)/HCO(3)(-) exchange inhibitors (4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid disodium salt hydrate and 4-acetamido-4'-isothiocyanato-2,2'-stilbenedisulfonic acid disodium salt hydrate) blocked secretin-stimulated fluid accumulation in PCK but not in normal cysts. Our data suggest that hepatic cystogenesis in autosomal recessive polycystic kidney disease may involve increased fluid accumulation because of overexpression and abnormal location of AQP1, CFTR, and AE2 in cystic cholangiocytes. Therapeutic interventions that block the activation of these proteins might inhibit cyst expansion in polycystic liver disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18988797      PMCID: PMC2626376          DOI: 10.2353/ajpath.2008.080125

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

1.  Modified culture conditions enhance expression of differentiated phenotypic properties of normal rat cholangiocytes.

Authors:  K D Salter; R M Roman; N R LaRusso; J G Fitz; R B Doctor
Journal:  Lab Invest       Date:  2000-11       Impact factor: 5.662

2.  Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion.

Authors:  Tonghui Ma; Jay R Thiagarajah; Hong Yang; Nitin D Sonawane; Chiara Folli; Luis J V Galietta; A S Verkman
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases.

Authors:  Luca Fabris; Massimiliano Cadamuro; Romina Fiorotto; Tania Roskams; Carlo Spirlì; Saida Melero; Aurelio Sonzogni; Ruth E Joplin; Lajos Okolicsanyi; Mario Strazzabosco
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

4.  The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein.

Authors:  Christopher J Ward; Marie C Hogan; Sandro Rossetti; Denise Walker; Tam Sneddon; Xiaofang Wang; Vicky Kubly; Julie M Cunningham; Robert Bacallao; Masahiko Ishibashi; Dawn S Milliner; Vicente E Torres; Peter C Harris
Journal:  Nat Genet       Date:  2002-02-04       Impact factor: 38.330

5.  Agonist-induced coordinated trafficking of functionally related transport proteins for water and ions in cholangiocytes.

Authors:  Pamela S Tietz; Raul A Marinelli; Xian-Ming Chen; Bing Huang; Jonathan Cohn; Jolanta Kole; Mark A McNiven; Seth Alper; Nicholas F LaRusso
Journal:  J Biol Chem       Date:  2003-03-26       Impact factor: 5.157

6.  Rat hepatocyte aquaporin-8 water channels are down-regulated in extrahepatic cholestasis.

Authors:  Flavia I Carreras; Sergio A Gradilone; Amelia Mazzone; Fabiana García; Bing Q Huang; J Elena Ochoa; Pamela S Tietz; Nicholas F Larusso; Giuseppe Calamita; Raúl A Marinelli
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

7.  PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats.

Authors:  Luiz F Onuchic; Laszlo Furu; Yasuyuki Nagasawa; Xiaoying Hou; Thomas Eggermann; Zhiyong Ren; Carsten Bergmann; Jan Senderek; Ernie Esquivel; Raoul Zeltner; Sabine Rudnik-Schöneborn; Michael Mrug; William Sweeney; Ellis D Avner; Klaus Zerres; Lisa M Guay-Woodford; Stefan Somlo; Gregory G Germino
Journal:  Am J Hum Genet       Date:  2002-03-15       Impact factor: 11.025

8.  Polaris, a protein disrupted in orpk mutant mice, is required for assembly of renal cilium.

Authors:  Bradley K Yoder; Albert Tousson; Leigh Millican; John H Wu; Charles E Bugg; James A Schafer; Daniel F Balkovetz
Journal:  Am J Physiol Renal Physiol       Date:  2002-03

9.  Channel-mediated water movement across enclosed or perfused mouse intrahepatic bile duct units.

Authors:  Ai-Yu Gong; Anatoly I Masyuk; Patrick L Splinter; Robert C Huebert; Pamela S Tietz; Nicholas F LaRusso
Journal:  Am J Physiol Cell Physiol       Date:  2002-07       Impact factor: 4.249

10.  Identification and characterization of Pkhd1, the mouse orthologue of the human ARPKD gene.

Authors:  Yasuyuki Nagasawa; Sonja Matthiesen; Luiz F Onuchic; Xiaoying Hou; Carsten Bergmann; Ernie Esquivel; Jan Senderek; Zhiyong Ren; Raoul Zeltner; Laszlo Furu; Ellis Avner; Markus Moser; Stefan Somlo; Lisa Guay-Woodford; Reinhard Büttner; Klaus Zerres; Gregory G Germino
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

View more
  34 in total

Review 1.  STAT signaling in polycystic kidney disease.

Authors:  Sebastian Strubl; Jacob A Torres; Alison K Spindt; Hannah Pellegrini; Max C Liebau; Thomas Weimbs
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

Review 2.  Physiology of cholangiocytes.

Authors:  James H Tabibian; Anatoliy I Masyuk; Tetyana V Masyuk; Steven P O'Hara; Nicholas F LaRusso
Journal:  Compr Physiol       Date:  2013-01       Impact factor: 9.090

3.  Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Authors:  Patricia Munoz-Garrido; José J G Marin; María J Perugorria; Aura D Urribarri; Oihane Erice; Elena Sáez; Miriam Úriz; Sarai Sarvide; Ainhoa Portu; Axel R Concepcion; Marta R Romero; María J Monte; Álvaro Santos-Laso; Elizabeth Hijona; Raúl Jimenez-Agüero; Marco Marzioni; Ulrich Beuers; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Joost P H Drenth; Jesús M Banales
Journal:  J Hepatol       Date:  2015-06-01       Impact factor: 25.083

4.  TGR5 in the Cholangiociliopathies.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Dig Dis       Date:  2015-05-27       Impact factor: 2.404

Review 5.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

6.  Requirements for ion and solute transport, and pH regulation during enamel maturation.

Authors:  Rodrigo S Lacruz; Charles E Smith; Pierre Moffatt; Eugene H Chang; Timothy G Bromage; Pablo Bringas; Antonio Nanci; Sanjeev K Baniwal; Joseph Zabner; Michael J Welsh; Ira Kurtz; Michael L Paine
Journal:  J Cell Physiol       Date:  2012-04       Impact factor: 6.384

7.  Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.

Authors:  Aura D Urribarri; Patricia Munoz-Garrido; María J Perugorria; Oihane Erice; Maite Merino-Azpitarte; Ander Arbelaiz; Elisa Lozano; Elizabeth Hijona; Raúl Jiménez-Agüero; Maite G Fernandez-Barrena; Juan P Jimeno; Marco Marzioni; Jose J G Marin; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Jesús M Banales
Journal:  Gut       Date:  2014-01-16       Impact factor: 23.059

8.  HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.

Authors:  Sergio A Gradilone; Stefan Habringer; Tatyana V Masyuk; Brynn N Howard; Anatoliy I Masyuk; Nicholas F Larusso
Journal:  Am J Pathol       Date:  2014-01-13       Impact factor: 4.307

Review 9.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

10.  Polycystic Liver Disease: The Benefits of Targeting cAMP.

Authors:  Nicholas F Larusso; Tatyana V Masyuk; Marie C Hogan
Journal:  Clin Gastroenterol Hepatol       Date:  2016-03-10       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.